8. Kopfschmerz zurückzuführen auf eine Substanz oder deren Entzug

• Literatur


8.1 Kopfschmerz induziert durch akuten Substanzgebrauch oder akute Substanzexposition
• Altura B.M., Altura B.T., Gebrewold A. Alcohol induced spasm of cerebral blood vessels. J Mental Sci 2000; 104: 972-999.
• Armstrong P.J., Bersten A. 1986; Normeperidine toxicity. Anesth Analg 65: 536-538.
• Ashina M, Bendtsen L, Jensen R, Olesen J. Nitric oxide-induced headache in patients with chronic tension-type headache. Brain 2000; 123: 1830-1837.
• Bouillabaisse: an outbreak of methemoglobinemia in New Jersey in. 1992; Pediatrics 94: 381-384.
• Askmark H, Lundberg P.O., Olsson S. Drug related Headache. Headache 1989; 29: 441-444 Atkins, F.M. (1986). A critical evaluation of clinical trials in adverse reactions to foods in adults. J Allergy Clin Immunol. 78:174-182.
• Beck H.G., Schulze W.H., Suter G.M.. 1940; Carbon monoxide-a domestic hazard. JAMA 115: 1.
• Bonnet G.F., Nepveux P. 1971; Migraine due to tyramine. Sem Hop 47: 2441-2445.
• Brewerton T.D., Murphy D.L., Lesem M.D., Brandt H.A., Jimerson D.C.. 1992; Headache responses following m-chlorophenylpiperazine in bulimics and controls. Headache 32: 217-22.
• Catalano G, Catalano M.C., Rodriguez R. 1997; Dystonia associated with crack cocaine use. South Med J 90: 1050-1052.
• Cleophas T.J., Niemeyer M.G., vanderWall E.E., vanderMeulen J. 1996; Nitrate-induced headache in patients with stable angina pectoris: beneficial effect of starting on a low dose. Angiology 47: 679-685.
• Council of Affairs Scientific. 1985; Aspartame: review of safety issues. JAMA 254: 400-402.
• Cregler L.L., Mark H. 1986; Medical complications of cocaine abuse. N Engl J Med 315: 1495-1501.
• Dalton K. 1976; Migraine and oral contraceptives. Headache 15: 247-251.
• Dhopesh V, Maany I, Herring C. 1991; The relationship of cocaine to headache in polysubstance abusers. Headache 31: 17-19.
• Dhuna A, Pascual-Leone A, Belgrade M. Cocaine-related vascular headaches. J Neurol Neurosurg Psychiat 1991; 54: 803-6.
• De Marinis M, Janiri L, Agnoli A. Headache in the use and withdrawal of opiates and other associated substances of abuse. Headache 1991; 31: 159-163.
• Ekbom K. 1968; Nitroglycerin as a provocative agent in cluster headache. Arch Neurol 19: 487-493.
• el-Mallakh R.S.. 1987; Marijuana and migraine. Headache 27: 442-443.
• el-Mallakh R.S., Kranzler H.R., Kamanitz J.R.. 1991; Headaches and psychoactive substance use. Headache 31: 584-587.
• Forbes H.S., Cobb S, Fremont-smith F. 1924; Cerebral edema and headache following carbon monoxide asphyxia. Arch Neurol Psychiatr 11: 164.
• Gawin F.H.. 1991; Cocaine addiction: psychology and neurophysiology. Science 251: 1580-1586.
• Ghose K, Carrol J.D.. 1984; Mechanisms of tyramine-induced migraine: similarities with dopamine and interactions with disulfiram and propranolol. Neuropsychiobiol 12: 122-126.
• Gordon C.R., Mankuta D, Shupak A, Spitzer O, Doweck I. 1991; Recurrent classic migraine attacks following transdermal scopolamine intoxication. Headache 31: 172-174.
• Gore M.E., Salmon P.R.. Chinese restaurant syndrome: fact or fiction. Lancet 1980; 318: 251-2.
• Hanington E, Harper A.M.. 1968; The role of tyramine in the etiology of migraine and related studies on the cerebral and intracerebral circulations. Headache 08: 84-97.
• Hansen H.J., Drewes V.M.. 1970; The nitroglycerine ointment test-a double-blind examination. Dan Med Bull 17: 226-229.
• Heckerling P.S., Leikin J.B., Maturen A, Perkins J.T.. 1987; Predictors of occult carbon monoxide poisoning in patients with headache and dizziness. Ann Int Med 107: 174-176.
• Henderson W.R., Raskin N.H.. 1972; »Hot dog« headache: individual susceptibility to nitrite. Lancet 02: 1162-1163.
• Hirsch A.R., Rankin K.M., Panelli P.P.. 1996; Trichloroethylene exposure and headache. Headache Quarterly 07: 126-138.
• Horowitz L.D., Herman M.V., Gorlin R. 1972; Clinical response to nitroglycerine as a diagnostic test for coronary artery disease. Am J Cardiol 29: 149-153.
• Iversen H.K., Nielsen T.M., Olesen J, Tfelt-Hansen P. 1989; Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 38: 17-24.
• Kenney R.A., Tidball C.S.. 1972; Human susceptibility to oral monosodium 1-glutamate. Am J Clin Nutr 25: 140-146.
• Kerr G.R., Lee M.W., elLozy M, McGandy R, Stare F. 1979; Prevalence of the »Chinese restaurant syndrome«. J Am Diet Assoc 75: 29-33.
• Krabbe A.A., Olesen J. 1980; Headache provocation by continuous intravenous infusion of histamine, clinical results and receptor mechanisms. Pain 08: 253-259.
• Larkin J.M., Brahos G.J., Moylin J.A.. 1976; Treatment of carbon monoxide poisoning: prognostic factors. J Trauma 16: 111.
• Lassen L.H., Thomsen L.L., Olesen J. 1995; Histamine induces migraine via the H receptor. Support for the NO-hypothesis of migraine. Neuroreport 06: 1475-1479.
• Leon A.S., Hunninghake D.B., Bell C, Rassin D.K., Tephly T.R.. 1989; Safety of long-term doses of aspartame. Arch Int Med 149: 2318-2324.
• Leone M, Attanasio A, Croci D, Filippini G, D’Amico D, Grazzi L, Nespolo A, Bussone G. 2000; The serotonergic agent m-chlorophenylpiperazine induced migraine attacks: a controlled study. Neurology 55: 136-139.
• Levine S.R., Brust J.C., Futrell N. et al. 1990; Cerebrovascular complications of the use of the crack form of alkaloidal cocaine. N Engl J Med 323: 699-704.
• Lipton R.B., Kwong C.M., Solomon S. Headaches in hospitalized cocaine users. Headache 1989; 29: 225-8.
• Lowenstein D.H., Massa S.M., Rowbotham M.C.. et al. 1987; Acute neurologic and psychiatric complications associated with cocaine abuse. Am J Med 83: 841-846.
• Luthy J, Schlatter C. 1983; Biogenic amines in food: effects of histamine, tyramine and phenylethylamine in the human. Z Lebensm Unters Forsch 177: 439-443.
• Magos A.L., Brewster E, Singh R, O’Dowd T, Brincat M, Studd J.W.W. 1986; The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome. Br J Obstet Gynaecol 93: 1290-1296.
• McCullock J, Harper A.M.. 1978. Phenylethylamine and the cerebral circulation. In: Current concepts in migraine research. Mc-Cullock J, Harper A.M.. eds. 85-88 Raven Press; New York:
• Meigs J.L., Hughes J.P.. 1952; Acute carbon monoxide poisoning: an analysis of 105 cases. AMA Arch Ind Hygiene Occupat Med 06: 344-356.
• Merkel P.A., Koroshetz W.J., Irizarry M.C., Cudkovicz M.E.. 1995; Cocaine-associated cerebral vasculitis. Semin Arthritis Rheum 25: 172-183.
• Merrit J.E., Williams P.B.. 1990; Vasospasm contributes to monosodium glutamate-induced headache. Headache 30: 575-580.
• Mitchell J.D.. 1995. Clinical neurotoxicology: In: Handbook of clinical neurology. DeWolff F.A.. ed. 1-22 Elsevier Science;
• Moffet A.M., Swash M, Scott D.F.. 1974; Effect of chocolate in migraine: a double-blind study. J Neurol Neurosurg Psychiatry 37: 445-448.
• Monteiro J.M.. 1993. Headache associated with single use of substances. In: The headaches. Olesen J, Tfelt-Hansen P, Welch K.M.A. eds.) 715-720 Raven Press, Limited; New York:
• Monteiro J.M., Dahlof C.G.. 2000. Single use of substances. In: The Headaches. Olesen J, Tfelt-Hansen P, Welch K.M.. eds. 861-869 Lippincott Williams & Wilkins; Philadelphia:
• Murphree A.B., Greenberg L.A., Carrol R.B.. 1967; Neuropharmacologic effects of substances other than ethanol in alcoholic beverages. Fed Proc 26: 1468-1473.
• Nappi R.E., Cagnacci A, Granella F, Piccinini F, Polatti F, Facchinetti F. 2001; Course of primary headaches during hormone replacement therapy. Maturitas 38: 157-63.
• Norton S. 1975. Toxicology of the central nervous system. In: Toxicology. Casarett L.J., Doult J. eds. 1019-1035 MacMillan; New York:
• Ogata S, Hosoi T, Saji H. Studies on acute alcohol intoxication. Japanese Journal of Studies of Alcohol 1966; 01: 67-79.
• Peters G.A.. 1953; Migraine: diagnosis and treatment with emphasis on the migraine-tension headache, provocative tests and use of rectal suppositories. Proc Mayo Clin 28: 673-686.
• Reif-Lehrer L. 1977; A questionnaire study of the prevalence of Chinese restaurant syndrome. Fed Proc 36: 1617-1623.
• Sabatini U, Rascol O, Rascol A, Montastruc J.L.. 1990; Migraine attacks induced by subcutaneous apomorphine in two migrainous Parkinson Ian patients. Clin Neuropharmacol 13: 264-267.
• Satel S.L., Gawin F.H.. 1989; Migraine-like headache and cocaine use. JAMA 261: 2995-2996.
• Schamburg H.H., Byck R, Gerstl R, Mashman J.H.. 1969; Monosodium L-glutamate: its pharmacology and role in the Chinese restaurant syndrome. Science 163: 826-828.
• Scher W, Scher B.M.. 1992; A possible role for nitric oxide in glutamate (MSG)-induced Chinese restaurant syndrome, glutamate induced asthma, »hot-dog headache«, pugilistic Alzheimer’s disease, and other disorders. Med Hypotheses 38: 185-188.
• Schiffmann S.S., Buckley C.E., Sampson H.A.. et al. 1987; Aspartame and susceptibility to headache. N Engl J Med 317: 1181-1185.
• Schnitker M.T., Schnitker M.A.. 1947; Clinical notes, suggestions and new instruments. J Amer Med Assoc 135: 89.
• Schwartz A.M.. 1946; The cause, relief and prevention of headache arising from contact with dynamite. N Engl J Med 235: 541-544.
• Scopp A.L.. 1991; MSG and hydrolyzed vegetable protein induced headache review and case studies. Headache 31: 107-110.
• Seltzer S. 1982; Foods and drug combinations, responsible for head and neck pain. Cephalalgia 02: 111-124.
• Shaw S.W., Johnson R.H., Keogh H.G.. 1978. Oral tyramine in dietary migraine sufferers. In: Current concepts in migraine research. Shaw S.W., Johnson R.H., Keogh H.G.. eds31-39 Raven Press; New York:
• Shively M, Riegel B. 1991; Effect of nitroglycerin ointment placement on headache and flushing in health subjects. Int J Nurs Stud 28: 153-161.
• Sicuteri F, Bene E.D., Poggioni M, Bonazzi A. 1987; Unmasking latent dysnociception in healthy subjects. Headache 27: 180-185.
• Smith I, Kellow A.H., Hanington E. 1970; Clinical and biochemical correlation between tyramine and migraine headache. Headache 10: 43-52.
• Tarasoff L, Kelly M.F.. 1993; Monosodium Lglutamate: a double-blind study and review. Food Chem Toxicol 31: 1019-1035.
• Thomsen L.L., Kruse C, Iversen H.K., Olesen J. A Nitric oxide donor triggers genuine migraine attacks. Eur J Neurol 1994; 01: 71-80.
• Towers C.V., Pircon R.A., Nageotte M.P., Porto M, Garite T.J.. 1993; Cocaine intoxication presenting as preeclampsia and eclampsia. Ob Gyn 81: 545-547.
• Trelles L, Jeri R. Central nervous system stimulants: cocaine, amphetamine, nicotine. In: Handbook of clinical neurology. DeWolff F.A.. ed. New York: Elsevier Science; 1995: 251-7.
• Wallgreen H, Barry A. Drug actions in relation to alcohol effects. In: Action of alcohol. New York: Elsevier; 1970: 621-714.
• Wilson J. 1995. Cyanogenic glycosides. Ch. 3 in Handbook of clinical neurology. vol. 65 DeWolff F.A.. ed. New York: Elsevier Science; 1995 25-34.
• Varon J, Marik P.E., Fromm R.E., Gueler A. Carbon Monoxide Poisoning: a review for clinicians. J. Emerg Med 1999; 17: 87-93.
• Yang W.H., Drouin M.A., Herbert M, Mao Y, Kursh J. 1997; The monosodium glutamate symptom complex: assessment in a double blind, placebo controlled, randomized study. J Allergy Clin Immunol 99: 757-762.

8.2 Kopfschmerz bei Medikamentenübergebrauch
• Ala-Hurula V, Myllyla V, Hokkanen E. 1982; Ergotamine abuse: results of ergotamine discontinuation with special reference to the plasma concentrations. Cephalalgia 02: 189-195.
• Ala-Hurula V, Myllyla V, Hokkanen E, Tokola O. 1981; Tolfenamic acid and ergotamine abuse. Headache 21: 240-242.
• Allgulander C. 1986; History and current status of sedative-hypnotic drug use and abuse. Acta Psychiatr Scand 73: 465-478.
• Andersson P.G.. 1975; Ergotamine headache. Headache 15: 118-121.
• Baar H.A.. 1990; Treatment for headache: a fourstep standardized withdrawal program for analgesic abusers. Pain Clin 03: 173-177 (Abstract).
• Bennett W.M., DeBroe M.E.. 1989; Analgesic nephropathy: a preventable renal disease. N Eng J Med 320: 1269-1271.
• Bowdler I, Killian J, Gänsslen-Blumberg S. The association between analgesic abuse and headache—coincidental or causal. Headache 1988; 28: 494.
• Braithwaite R.A.. The toxicity of tricyclic and newer antidepressants. In: Handbook of Clinical Neurology. DeWolff F.A.. ed. 311-320 New York: Elsevier Science; 1995: 311-20.
• Brust J.C.. 1995. Opiate addiction and toxicity. Ch. 16 in Handbook of clinical neurology. vol. 65 DeWolff F.A.. ed. New York: Elsevier Science; 356-361.
• Catarci T, Fiacco F, Argentino C. 1994; Ergotamine-induced headache can be sustained by sumatriptan daily intake. Cephalalgia 14: 374-375.
• Centonze V, Polite B.M., diBari M, Caporaletti P, Albano O. 1993; Vascular injuries in ergotamine abuse: a case report. Funct Neurol 08: 265-270.
• Dalquen P, Fasel J, Mihatsch M.J., Rist M, Rutishauser G. 1980; Phenacetinabusus IV. Sind zytologische harnuntersuchungen in der tumorvorsorge bei phenacetinabusern erfolgversprechend und anwendbar. Schweizerische Medizinische Wochenschrift 110: 302-306.
• DeBroe M.E., Elseviers M.M.. 1993; Analgesic nephropathy—still a problem?. Nephron 64: 505-513.
• deMarinis M, Janiri L, Agnoli A. 1991; Headache in the use and withdrawal of opiates and other associated substances of abuse. Headache 31: 159-163.
• Diamond S, Dalessio D.J.. 1982. Drug abuse in headache. In: The practicing physician’s approach to headache. Diamond S, Dalessio D.J.. eds. 114-121 Williams & Wilkins, Baltimore;
• Dichgans J, Diener H.C.. 1988. Clinical manifestations of excessive use of analgesic medication. In: Drug-induced headache. Diener H.C., Wilkinson M. eds. 8-15 Springer-Verlag; Berlin:
• Dichgans J, Diener H.D., Gerber W.D.. et al. 1984; Analgetika-induzierter dauerkopfschmerz. Dtsch Med Wschr 109: 369-73.
• Diener H.C.. 1993; A personal view of the classification and definition of drug dependence headache. Cephalalgia 13: 68-71.
• Diener H.C., Dahlof C.G.. 1999. Headache associated with chronic use of substances. In: The headaches. Olesen J, Tfelt-Hansen P, Welch K.M.A. eds. 871-878 Lippincott, Williams & Wilkins; Philadelphia:
• Diener H.C., Dichgans J, Scholz E, Geiselhart S, Gerber W.D., Bille A. 1989; Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 236: 9-14.
• Diener H.C., Haab J, Peters C, Ried S, Dichgans J, Pilgrim A. 1991; Subcutaneous sumatriptan in the treatment of headache during withdrawal from drug-induced headache. Headache 31: 205-209.
• Diener H.C., Pfaffenrath V, Soyka D, Gerber W.D.. 1992; Therapie des medikamenten-induzierten dauerkopfschmerzes. Münch Med Wschr 134: 159-162.
• Diener H.C., Tfelt-Hansen P. 1993. Headache associated with chronic use of substances. In: The headaches. Olesen J, Tfelt-Hansen P, Welch K.M.A. eds. 721-727 Raven press LTD; New York:
• Dige-Petersen H, Lassen N.A., Noer J, Toennesen K.H., Olesen J. 1977; Subclinical ergotism. Lancet i: 65-66.
• Drucker P, Tepper S. 1998; Daily sumatriptan for detoxification from rebound. Headache 38: 687-690.
• Dubach U.C., Rosner B, Pfister E. 1983; Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979). N Engl J Med 308: 357-362.
• Elkind A.H.. 1989; Drug abuse in headache patients. Clin J Pain 05: 111-120.
• Elkind A.H.. 1991; Drug abuse and headache. Med Clin N Am 75: 717-732.
• Evers S, Gralow I, Bauer B, Suhr B, Buchheister A, Husstedt I.W., Ringelstein E.B.. 1999; Sumatriptan and ergotamine overuse and druginduced headache: a clinicoepidemiologic study. Clin Neuropharmacol 22: 201-206.
• Fanciullaci M, Alessandri M, Pietrini U, Briccolani-Bandini E, Beatrice S. 1992; Longterm ergotamine abuse: effect on adrenergically induced mydriasis. Clin Pharm Ther 51: 302-307.
• Fincham J.E.. 1987; Over-the-counter drug use and misuse by the ambulatory elderly: a review of the literature. J Ger Drug Ther 01: 3-21.
• Fincham R.W., Perdue Z, Dunn V.D.. 1985; Bilateral focal cortical atrophy and chronic ergotamine abuse. Neurology 35: 720-722.
• Fisher C.M.. 1988; Analgesic rebound headache refuted. Headache 28: 666.
• Friedman A.P., Brazil P, vonStorch T.J.. 1955; Ergotamine tolerance in patients with migraine. JAMA 157: 881-884.
• Gaist D, Hallas J, Sindrup S.H., Gram L.F.. 1996; Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol 50: 161-165.
• Gaist D, Tsiropoulus I, Sindrup S.H., Hallas J, Rasmussen B.K., Kragstrup J. 1998; Inappropriate use of sumatriptan: population based register and interview study. Br J Med 316: 1352-1353.
• Granella F, Farina S, Malferrari G, Manzoni G.C.. 1987; Drug abuse in chronic headache: a clinicoepidemiologic study. Cephalalgia 07: 15-19.
• Gutzwiller F, Zemp E. 1986. Der analgetikakonsum in der bevölkerung und socioökonomische aspekte des analgetikaabusus. In: Das analgetikasyndrom. Mihatsch M.J.. ed. 197-205 Thieme, Stuttgart;
• Hering R, Steiner T.J.. 1991; Abrupt outpatient withdrawal from medication in analgesicabusing migraineurs. Lancet 337: 1442-1443.
• Hokkanen E, Waltimo O, Kallanranta T. 1978; Toxic effects of ergotamine used for migraine. Headache 18: 95-98.
• Horowski R, Ziegler A. 1988. Possible pharmacological mechanisms of chronic abuse of analgesics and other antimigraine drugs. In: Drug-induced headache. Diener H.C., Wilkinson M. eds. 95-104 Springer-Verlag; Berlin:
• Horton B.T., Peters G.A.. 1963; Clinical manifestations of excessive use of ergotamine preparations and management of withdrawal effect: report of 52 cases. Headache 03: 214-226.
• Isler H. 1982. Migraine treatment as a cause of chronic migraine. In: Advances in migraine re search and therapy. Rose F.C.. ed. 159-164 Raven Press, New York:
• Jaffe J.H.. 1985. Drug addiction and drug abuse. In: The pharmacological basis of therapeutics. Gilman A.G., Rall T.W., Nies A.S., Taylor P. eds. 522-573 Pergamon Press; New York:
• Katsarava Z, Fritsche G, Muessig M, Diener H.C., Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001; 57: 1694-1698.
• Kaube H, May A, Diener H.C., Pfaffenrath V. 1994; Sumatriptan misuse in daily chronic headache. Br Med J 308: 1573.
• Kielholz P, Ladewig D. 1981; Probleme des medikamentenmi beta-brauches. Schweiz Arztezeitung 62: 2866-2869.
• Klapper J.A.. 1992; Rebound headache: definition, symptomatology, treatment, and prevention. Headache Quarterly 03: 398-402.
• Kouyanou K, Pither C.E., Rabe-Hesketh S, Wessely S. 1998; A comparative study of iatrogenesis, medication abuse, and psychiatric morbidity in chronic pain patients with and without medically explained symptoms. Pain 76: 417-426.
• Kudrow L. 1982; Paradoxical effects of frequent analgesic use. Adv Neurol 33: 335-341.
• Lader M. Hypnotics and sedatives. In: Handbook of clinical neurology. DeWolff F.A.. ed. New York: Elsevier Science: 1995: 329-55.
• Lance F, Parkes C, Wilkinson M. 1988. Does analgesic abuse cause headache de novo?. Headache. 61-62.
• Lance J.W.. 1990; A concept of migraine and the search for the ideal headache drug. Headache 30: 17-23.
• Limmroth V, Kazarawa S, Fritsche G, Diener H.C.. 1999; Headache after frequent use of new 5-HT agonists zolmitriptan and naratriptan. Lancet 353: 378.
• Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener H.C.. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59: 1011-1014.
• Lucas R.N., Falkowski W. 1973; Ergotamine and methysergide abuse in patients with migraine. Br J Psychiatry 122: 199-203.
• Ludolph A.C., Husstedt I.W., Schlake H.P., Grotemeyer K.H., Brune G.G.. 1988; Chronic ergotamine abuse: evidence of functional impairment of long ascending spinal tracts. Eur Neurol 28: 311-316.
• MacGregor E.A., Vorah C, Wilkinson M. 1990; Analgesic use: a study of treatments used by patients for migraine prior to attending the City of London migraine clinic. Headache 30: 634-638.
• Manzoni G.C., Micieli G, Granella F, Sandrini G, Zanferrari C, Nappi G. 1988. Therapeutic approach to drug abuse in headache patients. In: Drug-induced headache. Diener H.C., Wilkinson M. eds. 143-149 Springer-Verlag; Berlin:
• Marks V. 1981. Reactive (rebound) hypoglycemia). In: Hypoglycemia. Marks V, Rose C.F.. eds. 179-217 Blackwell, Oxford;
• Mathew N.T.. 1987; Amelioration of ergotamine withdrawal symptoms with naproxen. Headache 27: 130-133.
• Mathew N.T., Kurman R, Perez F. 1990; Drug induced refractory headache clinical features and management. Headache 30: 634-638.
• Michultka D.M., Blanchard E.B., Appelbaum K.A., Jaccard J, Dentinger M.P.. 1989; The refractory headache patient—2. High medication consumption (analgesic rebound) headache. Behav Res Ther 27: 411-420.
• Micieli G, Manzoni G.C., Granella F, Martignoni E, Malferrari G, Nappi G. 1988. Clinical and epidemiological observations on drug abuse in headache patients. In: Drug-Induced Headache. Diener H.C., Wilkinson M. eds. 20-28 Springer-Verlag; Berlin:
• Nicolodi M, DelBianco P.L., Sicuteri F. 1997; The way to serotonergic use and abuse in migraine. Int J Clin Pharmacol Res 17: 79-84.
• Page H. 1981; Rebound headache from ergotamine withdrawal. JAMA 246: 719.
• Peters G, Horton B.T.. 1951; Headache: with special reference to the excessive use of ergotamine preparations and withdrawal effects. Proc Mayo Clin 26: 153-161.
• Pini L.A., Trenti T. 1994. Case report: does chronic use of sumatriptan induce dependence?. Headache. 34 600-601.
• Pradalier A, Dry S, Baron J.F.. 1984; Cephalée induite par l’abuse de tartrate d’ergotamine chez les migrainieux. Concours Méd 106: 106-110.
• Rahman A, Segasothy M, Samad S.A., Zulfiqar A, Rani M. 1993; Analgesic use and chronic renal disease in patients with headache. Headache 33: 442-445.
• Rapoport A, Stang P, Gutterman D.L., Cady R, Markley H, Weeks R, Saiers J, Fox A.W.. 1996; Analgesic rebound headache in clinical practice: data from a physician survey. Headache 36: 14-19.
• Rapoport A.M.. 1988; a Analgesic rebound headache. Headache 28: 662-665.
• Rapoport A.M., Weeks R.E.. 1988. b Characteristics and treatment of analgesic rebound headache. In: Drug-induced headache. Diener H.C., Wilkinson M. eds. 162-167 Springer-Verlag; Berlin:
• Roswell A.R., Neylan C, Wilkinson M. 1973; Ergotamine induced headache in migrainous patients. Headache 13: 65-67.
• Sandler D.P., Smith J.C., Weinberg C.R., Buckalew V.M., Dennis V.W., Blythe W.B., Burgess W.P.. 1989; Analgesic use and chronic renal disease. N Engl J Med 320: 1238-1243.
• Saper J.R.. 1983. a Drug abuse among headache patients. In: Headache disorders. Saper J.R.. ed. 263-278 PSG Publishers; Boston:
• Saper J.R.. 1983; b Drug overuse among patients with headache. Neurol Clin 01: 465-477.
• Saper J.R.. 1990; Daily chronic headaches. Neurol Clin N Amer 08: 891-902.
• Saper J.R., Jones J.M.. 1986; Ergotamine tartrate dependency: features and possible mechanisms. Clin Neuropharmacol 09: 244-256.
• Schnider P, Aull S, Baumgartner C. et al. 1996; Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five-year followup. Cephalalgia 16: 481-485.
• Schnider P, Aull S, Feucht M. 1994; Use and abuse of analgesics in tension-type headache. Cephalalgia 14: 162-167.
• Schnider P, Maly J, Grunberger J, Aull S, Zeiler K, Wessely P. 1995; Improvement of decreased critical flicker frequency in headache patients with drug abuse after successful withdrawal. Headache 35: 269-272.
• Schoenen J, Lenarduzzi P, Sianard-Gainko J. 1989. Chronic headaches associated with analgesics and/or ergotamine abuse: a clinical survey of 434 consecutive outpatients. In: New advances in headache research. Rose F.D.. ed. 29-43 Smith-Gordon; London:
• Seller E.M., Busto U.E., Kaplan H.L., Somer G, Baylon G.J.. 1998; Comparative abuse liability of codeine and naratriptan. Clin Pharmacol Ther 63: 121.
• Shakir R.A.. 1995. Vitamin toxicity. In: Handbook of clinical neurology. vol. 65 DeWolff F.A.. ed. New York: Elsevier Science; 567-576.
• Silberstein S.D., Lipton R.B.. 1997. Chronic daily headache. In: Headache. Goadsby P.J., Silberstein S.D.. eds. 201-225 Butterworth-Heinemann; Newton:
• Silberstein S.D., Lipton R.B., Solomon S, Mathew N.T.. 1994; Classification of daily and near daily headaches: proposed revisions to the IHS classification. Headache 34: 1-7.
• Silberstein S.D., Silberstein J.R.. 1992; Chronic daily headache: prognosis following inpatient treatment with repetitive IV DHE. Headache 32: 439-445.
• Stewart J.H.. 1978; Analgesic abuse and renal failure in Australia. Kidney Internat’l 13: 72-78.
• Sullivan J.T., Sellers E.M.. 1986; Treatment of the barbiturate abstinence syndrome. Med J Aust 145: 456-458.
• Taschner K.L., Wiesbeck G.A.. 1988. Psychiatric aspects of drug addiction of the barbiturate-alcohol type. In: Druginduced headache. Diener H.C., Wilkinson M. eds. 80-84 Berlin, Springer-Verlag:
• Tfelt-Hansen P. 1985. Ergotamine headache. In Updating in headache. Pfaffenrath V, Lundberg P, Sjaastad O. eds. 169-172 Springer; Berlin:
• Tfelt-Hansen P. 1986; The effect of ergotamine on the arterial system in man. Acta Pharmacol Toxicol 59: 1-29.
• Tfelt-Hansen P, Krabbe A.A.. 1981; a Ergotamine. Do patients benefit from withdrawal? Cephalalgia 01: 29-32.
• Tfelt-Hansen P, Olesen J. 1981; b Arterial response to ergotamine tartrate in abusing and non-abusing migraine patients. Acta Physiol Scand 48: 69-72.
• Tfelt-Hansen P, Paalzow L. 1985; Intramuscular ergotamine: plasma levels and dynamic activity. Clin Pharmacol Ther 37: 29-35.
• Tfelt-Hansen P, Saxena P.R., Ferrari M.D.. 1995. Ergot alkaloids. In: Handbook of clinical neurology. DeWolff F.A.. ed. 61-67 New York: Elsevier Science;
• Timmings P.L., Richens A. 1995. Neurotoxicology of antiepileptic drugs. In: Handbook of clinical neurology. DeWolff F.A.. ed. 495-513 New York: Elsevier Science;
• Vasconcellos E, Pina-Garza J.E., Millan E.J., Warner J.S.. 1998; Analgesic rebound headache in children and adolescents. J Child Neurol 13: 443-447.
• Verhoeff N.P., Visser W.H., Ferrari M.D., Saxena P.R., vonRoyen E.A.. 1993; Dopamine D2 receptor imaging with 123-I-iodobenzamide SPECT in migraine patients abusing ergotamine: does ergotamine cross the blood brain barrier. Cephalalgia 13: 325-329.
• VonKorff M, Galer B.S., Stang P. 1995; Chronic use of symptomatic headache medications. Pain 62: 179-186.
• Walker J, Parisi S, Olive D. 1993; Analgesic rebound headache: experience in a community hospital. Southern Med J 86: 1202-1205.
• Warner J.S.. 1999; Rebound headaches: a review. Headache Quarterly 10: 207-219.
• Zed P.J., Loewen P.S., Robinson G. 1999; Medication-induced headache: overview and systematic review of therapeutic approaches. Ann Pharmacother 33: 61-72.
• Ziegler D.K.. 2000; Opiate and opioid use in patients with refractory headache. Cephalalgia 14: 5-10.

8.3 Kopfschmerz als Nebenwirkung zurückzuführen auf eine Dauermedikation
• de Lignières B, Silberstein S.D.. Pharmacodynamics of oestrogens and progestagens. Cephalalgia 2000; 20: 200-207.
• Silberstein S.D.. Hormone-related headache. M Clin N Am 2001; 85: 1017-1035.
• Silberstein S.D., de Lignières B. Migraine, menopause and hormonal replacement therapy. Cephalalgia 2000; 20: 214-212.

8.4 Kopfschmerz zurückzuführen auf den Entzug einer Substanz
• Abbott P.J.. 1986; Caffeine: a toxicological overview. Med J Aust 145: 518-521.
• Baumgartner G.R., Rowen R.C.. 1991; Transdermal clonidine versus chlordiazepoxide in alcohol withdrawal: a randomized, controlled clinical trial. South Med J 84: 312-321.
• Dalessio D.J.. 1980. Wolff’s headache and other head pain. Oxford University Press, Oxford:
• Epstein M.T., Hockaday J.M., Hockaday T.D.R. 1975; Migraine and reproductive hormones through the menstrual cycle. Lancet i: 543-548.
• Greden J.F., Fontaine M, Lubetsky M, Chamberlin K. 1978; Anxiety and depression associated with caffeinism among psychiatric inpatients. Am J Psychiatr 135: 963-966.
• Laska E.M., Sunshine A, Mueller F, Elvers W.B., Siegel C, Rubin A. 1984; Caffeine as an analgesic adjuvant. JAMA 251: 1711-1718.
• Lichten E, Lichten J, Whitty A, Pieper D. 1996; The confirmation of a biochemical marker for women’s hormonal migraine : the depo-oestradiol challenge test. Headache 36: 367-71.
• Raskin N.H., Appenzeller O. 1980. Headache, Saunders; Philadelphia:
• Silverman K, Evans S.M., Strain E.C., Griffiths R.R.. 1992; Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Eng J Med 327: 1109-1114.
• Somerville B. 1975; Estrogen withdrawal migraine. Neurology 25: 239-250.
• vanDusseldorp M, Katan M.B.. 1990; Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee: a 12 week double blind trial. Br Med J 300: 1558-1559.
• White B.C., Lincoln C.A., Pearcz N.W., Reeb R, Vaida C. 1980; Anxiety and muscle tension as consequence of caffeine withdrawal. Science 209: 1547-1548.